Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management

Vendrell, Julie A.; Mau-Them, Frédéric Tran; Béganton, Benoît; Godreuil, Sylvain; Coopman, Peter J.; Solassol, Jérôme

doi:10.3390/ijms18020264

Cited by 82 publications

(59 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy may be attributable to several factors. Because pre‐analysis conditions undoubtedly play a crucial role, slight differences in plasma DNA extraction and quantification methods in each laboratory may affect the detection rate of ctDNA. Moreover, the detection rate could vary depending on the threshold setting …”

Section: Discussionmentioning

confidence: 99%

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundThis study was conducted to identify whether the presence of circulating tumor DNA (ctDNA) in plasma before treatment with EGFR‐tyrosine kinase inhibitors (TKIs) is associated with clinical outcomes.MethodsFifty‐seven pairs of tissues and plasma samples were obtained from patients with NSCLC adenocarcinoma harboring activating EGFR mutations before the administration of EGFR‐TKI treatment. ctDNA mutation was identified using the PANAMutyper EGFR mutation kit. Both qualitative and quantitative analyzes of the data were performed.ResultsConcordance rates with tissue biopsy were 40.4% and 59.6% for the qualitative and quantitative methods, respectively. Bone metastasis showed a statistically significant correlation with ctDNA detection (odds ratio 3.985, 95% confidence interval [CI] 1.027–15.457; P = 0.046). Progression‐free survival (PFS) was significantly shorter in the group detected with ctDNA than in the undetected ctDNA group (median PFS 9.8 vs. 20.7 months; hazard ratio [HR] 2.30, 95% CI 1.202–4.385; P = 0.012). Detection of ctDNA before treatment with EGFR‐TKIs (HR 2.388, 95% CI 1.138–5.014; P = 0.021) and extra‐thoracic lymph node metastasis (HR 13.533, 95% CI 2.474–68.747; P = 0.002) were independently associated with PFS. Six of 11 patients (45.5%) monitored by serial sampling showed a dynamic change in ctDNA prior to disease progression.ConclusionQuantitative testing can increase the sensitivity of the ctDNA detection test. Patients with detectable ctDNA had significantly shorter PFS after receiving EGFR‐TKIs than those with undetectable ctDNA. Tumor burden may be associated with plasma ctDNA detection. A shorter PFS was associated with detection of ctDNA and extra‐thoracic lymph node metastasis. Dynamic changes in the ctDNA level may help predict clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…70 cfDNA/ctDNA are released in both apoptosis and necrosis of the cells at the interface of tumor and circulation, or active release. [71][72][73][74] Previously, it was believed that blood circulating nucleic acids were solely released by necrosis. However, Jahr et al reported that apoptosis plays a role in this process as well.…”

Section: Ctdna/cfdna: Physiological Characteristics and Analysismentioning

confidence: 99%

Liquid biopsy in breast cancer: A comprehensive review

2019

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women worldwide. Due to its complexity in nature, effective breast cancer treatment can encounter many challenges. Traditional methods of cancer detection such as tissue biopsy are not comprehensive enough to capture the entire genomic landscape of breast tumors. However, with the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment. Various components of tumor cells released into the blood circulation can be analyzed in liquid biopsy sampling, some of which include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell‐free RNA, tumor‐educated platelets and exosomes. These components can be utilized for different purposes. As an example, ctDNA can be sequenced for genetic profiling of the tumors to enhance individualized treatment and longitudinal screening. CTC plasma count analysis or ctDNA detection after curative tumor resection surgery could facilitate early detection of minimal residual disease, aiding in the initiation of adjuvant therapy to prevent recurrence. Furthermore, CTC plasma count can be assessed to determine the stage and prognosis of breast cancer. In this review, we discuss the advantages and limitations of the various components of liquid biopsy used in breast cancer diagnosis and will expand on aspects that require further focus in future research.

show abstract

“…Hence, a blood sample is undoubtedly the more desirable alternative (Francis and Stein, 2015;Lowes et al, 2016). Furthermore, using this kind of methodology was successful in revealing pancreatic, lung, breast, and prostate cancer onset in patients but also melanomas in early-stage development through the cfDNA (Haber and Velculescu, 2014;Earl et al, 2015;Iwama et al, 2017;Oellerich et al, 2017;Takai and Yachida, 2016;Vendrell et al, 2017). Iwama and colleagues demonstrated that the use of dPCR in patients' liquid biopsy of lung adenocarcinoma was able to detect the EGFR "activating mutation" in cfDNA at a high rate of 81.3% and 100%, compared with Next Generation Sequencing (NGS) with 71.7 and 60.0%).…”

Section: Cell-free Dna (Cfdna) and Circulating Tumor Cellsmentioning

confidence: 99%

The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell‐free DNA and circulating tumor cells

Melo-Silva

Lucena

Hueneburg

2019

Cell Biology International

View full text Add to dashboard Cite

Cancer is one of the most important causes of death worldwide. The onset of cancer may be initiated due to a variety of factors such as environment, genetics or even due to personal lifestyle choices. To counteract this tremendous increase, the demand for a new technology has risen. By this means, the use of digital polymerase chain reaction (dPCR) has been shown to be a promising methodology in the early detection of many types of cancers. Furthermore, several researchers confirmed that the use of tumor cell‐free DNA (cfDNA) and circulating tumor cells (CTC) in peripheral blood is essential in revealing an early prognosis of such diseases. Besides this, it was established that dPCR might be used in a much more efficient, accurate, and reliable manner to amplify a variety of genetic material up to the identification of mutations in hematological diseases. Therefore, this article demonstrates the differences between conventional PCR and dPCR as a molecular technique to detect the early onset of cancer. Furthermore, CTC and cfDNA were officially approved by the Food and Drug Administration as new biological biomarkers in cancer development and monitoring.

show abstract

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management

Cited by 82 publications

References 116 publications

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

Liquid biopsy in breast cancer: A comprehensive review

The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell‐free DNA and circulating tumor cells

Contact Info

Product

Resources

About